The global demand for Alprolix Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022 - 2028. Regarding volume, the market was calculated XX Kilo Tons in 2021 and forecast to touch XX Kilo Tons by 2028 with a CAGR of XX% during 2022-2028.
Alprolix is an intravenous injection used to treat bleeding in patients with haemophilia B and the severity of the patient's factor IX deficiency. Haemophilia B an inherited bleeding disorder caused by a lack of a clotting protein called factor IX. Alprolix contains the active substance eftrenonacog alfa, which works in the body similarly to human factor IX. Alprolix replaces the missing factor IX, helping the blood to clot and giving temporary control of bleeding. It is available as a powder and solvent mixed to make a solution for injection into a vein. Alprolix is sold under the brand name AlphaNine SD, Ixinity, Mononine, Rebinyn, Rixubis, Alprolix, BeneFIX, and Idelvion.
Market Dynamics
The global alprolix market will witness a steady rise in the coming years. Significant rise in the Hemophilia B incidence worldwide and growing approvals for commercial use is increasing alprolix demand. Hemophilia B constitutes about 20% of hemophilia cases that occur in approximately 1 in 25,000 male births. Health Canada approved Alprolix in March 2014, Biogen idec received the US Food and Drug Administration's (FDA) approval for Alprolix in March 2014 for the control and prevention of bleeding episodes, perioperative (surgical) management, and routine prophylaxis in adults and children with haemophilia B. In addition, the European Committee for Medicinal Products for Human Use (CHMP) approved Alprolix in May 2016. Alprolix has also received approval from regulatory authorities in Australia, Japan, and New Zealand. Alprolix is under research and clinical trial in many countries, and more approvals are yet to come. However, the presence of other alternative medications to treat haemophilia B symptoms is limiting the market growth.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of alprolix. The growth and trends of Alprolix Industry provide a holistic approach to this study.
Market Segmentation
This section of the alprolix market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
By Application
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Alprolix market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Alprolix Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the alprolix market include Biogen Idec Sobi Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.